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Introduction 
The course of Graves' disease (GD) is associated with
the inflow of lymphocytes to the thyroid gland and
dysregulation of the immune system characterized by
reaction to thyroid antigens (peroxidase, thyroglobu-
lin, TSH receptors and Na+/I- symporter). After acti-
vation they shift to the inflamed thyroid gland, thus
leading to the production of cytokines which can stim-
ulate activity of thyrocytes and increase expression on
intracellular proapoptotic markers such as TIAR and
TIA-1.
T-cell intracellular antigen 1 (TIA-1) and TIA-1-
related protein (TIAR) are the RNA-binding proteins.
They consist of three RNA recognition motifs (RRMs)
and a glutamine-rich carboxyl-terminal domain [1].
Both proteins play role in nuclear and cytoplasmic
RNA metabolism, in pre-mRNA splicing and mRNA
translation. TIA-1 has been identified as an important
splicing regulator in mammals. It was proven that
TIA-1 regulates the alternative pre-mRNA splicing of
various human and Drosophila genes (FGFR-2, msl-2,
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Abstract: The aim of this study was to estimate sodium iodide symporter (NIS) and thyroid peroxidase (TPO) expression
in thyrocytes from patients with GD and no-toxic multinodular goitre (NTMG) in relationship with apoptotic (TIAR and
TIA-1) markers. The investigation was performed on thyroid cells isolated from postoperation thyroid tissues from 
15 patients aged 12-21 years old with GD and 15 cases aged 13-21 years old with NTMG. Detection of NIS and TPO was
performed by immunohistochemistry. Analysis of apoptotic markers in thyroid tissues was performed using antibodies to
TIAR and TIA-1 by Western Blot and immunohistochemistry. Identification of proapoptotic TIAR and TIA-1 molecules in
the thyroid tissues revealed a higher expression of both proteins in patients with Graves' disease (+++; +, respectively) in
comparison to patients with NTNG (+; 0). In addition, TIAR expression was detected in three bands [p50, p42, p38 (kDa)]
and TIA-1 in two bands [p22, p17 (kDa)]. using Western Blot test in patients with thyroid autoimmune diseases. In patients
with NTNG expression of both apoptotic proteins was lower and identified in single bands: 42 (kDa) for TIAR and 17 (kDa)
for TIA-1. The analysis of expression of NIS and TPO in thyroid follicular cells was higher in patients with Graves' disease
in compared to their detection in patients with NTMG. In addition, degree of thyroid antigen expression positive correlated
with amount of proapoptotic markers (TIAR, p<0.001; TIA-1, p<0.025 for NIS; TIAR, p<0.012 for TPO). We conclude that
elevated expression of NIS and TPO in Graves' disease is associated with higher stimulation and activation of apoptosis in
thyroid follicular cells during autoimmune process. 
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TIAR, cystic fibrosis transmembrane conductance reg-
ulator and Fas) through binding to U-rich stretches,
facilitating atypical 5-splice site recognition by U1
small nuclear ribonucleoprotein [2,3].
TIA-1 has also been well characterized as a transla-
tional regulator. TIA-1 and TIAR are both able to bind
to the 3-untranslated regions of the translational regu-
latory AU-rich elements of tumor necrosis factor,
human matrix metalloproteinases-13, cyclooxygenase-
2 , 2-adrenergic receptor, mitochondrial cytochrome c,
GADD45 and -F1-ATPase mRNAs [4-10].
These both protein may also promote cellular and
virus-induced apoptosis, to be implicated in viral repli-
cation and to be required for DT40 cell viability. TIA-
1 plays also important functions in apoptotic cell death
and in adapting the cellular response to metabolic
stress and inflammation. TIAR is translocated from the
nucleus to the cytoplasm during Fas- mediated apopto-
sis. TIA-1 is a specific substrate for the Fas- activated
protein serine/ threonine kinase [10].
The isoforms of both mTIA-1 and mTIAR are pre-
dominantly expressed in brain, spleen and testis and
mTIAR is also expressed in liver and lung. mTIA-1
and mTIAR are not expressed or only very weakly, in
the other tissues tested such as heart, skeletal muscle
and kidney [11].
The aim of this study was to estimate sodium iodide
symporter (NIS) and thyroid peroxidase (TPO) expres-
sion in thyrocytes from patients with GD and no-toxic
multinodular goiter (NTMG) in relation to the apop-
totic markers.
Material and methods 
Patients and study material. The study was performed in a group
of 30 adolescent patients (8 boys and 22 girls) aged 8-21 years with
GD (n=15, mean age 13.9±3.5 years) and nontoxic nodular goiter
(NTNG; n=20, mean age 15.8±2.2 years) hospitalized in the
Department of Pediatrics, Endocrinology, Diabetology with 
Cardiology Division, Medical University of Bia³ystok and in the
Department of Pediatric Endocrinology and Diabetology, Poznañ
University of Medical Sciences. The patients underwent total or
subtotal thyroidectomy in the 1st Department of General Surgery,
Medical University of Bia³ystok or in the Department of Pediatric
Surgery, Poznañ University of Medical Sciences.
The diagnosis was established based on clinical examinations
confirmed by laboratory, ultrasonographic and scintigraphic inves-
tigations with the use of I131 (in case of nodular goiter with symp-
toms of hyperthyroidism). Additionally, fine-needle aspiration
biopsies of nodular goiter were performed in the Department of
Pathological Anatomy, Medical University of Bia³ystok. The qual-
ifying criteria for patients with GD were as follows: large goiter,
presence of ophthalmopathy, antibodies against receptor for thy-
roid stimulating hormone (TRAb) >5, positive titers of antithyroid
peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies
persisting over 2-3 months since the diagnosis of thyroid-stimulat-
ing hormone (TSH) <0.45.
Methimazole therapy, at the initial dose of 0.5-1.0 mg/kg/day,
was used in combination with propranolol 0.5-1.0 mg/kg/day to
treat hyperthyroidism in the course of GD and toxic nodular goiter.
A further reduction in methimazole dose and obtaining euthyrosis
prior to surgery depended on clinical-biochemical parameters.
Average daily doses of this antithyroid drug were 10-15 mg. Some
of the GD patients underwent combined treatment (antithyroiddrug
with thyroxine at a dose of 50-100 μg/day).
The function of the thyroid gland in patients with GD (as well
as in nodular goiter) was assessed at the time of diagnosis and prior
to surgery. Thyroid function was evaluated based on thyroid hor-
mones and TSH tests performed jointly with the measurement of
titers of antithyroid antibodies (ATPO, ATG, TRAK). The expres-
sion of proapoptotic proteins was identified in tissue material
obtained from patients with immune and nonimmune disorders.
Determination of the antithyroid antibody titers and thyroid
hormone concentration. Blood for analysis was collected on
empty stomach in the morning hours from the basilic vein and
centrifuged for 10 min at 2,000 rotations/min. Sera were stored at 
-20°C until the required number was collected. Immunodiagnos-
tic test Varelisa (Variable Enzyme Linked Immno Sorbent Assay,
Pharmacia Upjohn Diagnostics,GmbH & Co.KG., Freiburg, Ger-
many) was used to determine anti-peroxidase antibodies (anti-
TPO) and anti-TG antibodies in the sera, using human microso-
mal antigen and human thyroglobulin, respectively. The results
were read on a photometer (STAT FAX 303 PLUS, ANALCO-
GBG), at 450 nm of light wavelength for which absorption val-
ues were proportional to the level of anti-TPO or anti-TG anti-
bodies. The radioreceptor method (TRAK-human, Brahms Diag-
nostica, GmbH, Berlin, Germany) was employed to assess TRAb
in blood serum. The TRAb level was negative at the values
<1 U/l, doubtful between 1.0 and 1.5 U/l (grey zone) and positive
above 1.5 U/l.
Determination of serum thyrotropin hormone (TSH) was done
using a mini-analyzer VIDAS (bioMérieux) and VIDAS TSH test,
being a combination of the immunoenzymatic method and final
fluorescence measurement (ELFA). In the permanent phase, anti-
TSH mouse monoclonal antibodies were used. Normal values for
TSH ranged between 0.32 and 5.0 μIU/ml. Serum levels of free
thyroxine (fT4) and free triiodothyronine (fT3) were determined
on a mini-analyzer VIDAS based on VIDAS fT4 and VIDAS fT3
tests that combine the immunoenzymatic method with the final
measurement of fluorescence (ELFA). 
Normal values ranged between 0.71 and 1.55 ng/dl for fT4 and
between 2.6 and 5.4 ng/dl for fT3.
SDS-PAGE and Western Blotting. Tissue samples were
homogenized in an ice-cold buffer (250 mM sucrose, 20 mM
Tris-HCl, pH 7.4, 1 mM EDTA) containing a cocktail of protease
inhibitors (Roche Diagnostics, GmbH, Mannheim, Germany).
Homogenates were centrifuged at 1,000 g for 15 min at 4°C, then
at 100,000 g for 60 min at 4°C. The resulting pellets containing
particulate fractions were recovered, resuspended in 20 mM Tris-
HCl, pH 7.4 with 1 μg/ml phenyl-methylsulphonyl fluoride and
kept at -80°C. The protein concentrations were evaluated by the
bicinchronic acid protein assay reagent (Pierce Chemical, Co.,
Rockford, Ill., USA).
A total of 75 μg of crude membrane proteins was mixed with 
a protein buffer (0.25 mM Tris-HCl, pH 6.8, 20% glycerol, 4%
SDS, and 0.1% bromophenol blue) and incubated with 0.125 M
dithiothreitol for 30 min at 37°C. Each sample was loaded into
individual wells and electrophoresed on a 9% acrylamide, using
the SDS-PAGE method. Proteins were electrotransferred to
immunoblot PVDF membranes (Bio-Rad Laboratories, Hercules,
Calif., USA), which were then saturated with 5% powdered milk
in PBS-Tween. Western blotting experiments were subsequently
carried out by incubating the blotted membranes with mouse mon-
oclonal anti-human TIAR and TIA-1 antibodies (BD Biosciences
Pharmingen) diluted according to the manufacturer's suggestion
overnight at 4°C. After three washings in PBSTween for 10 min,
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the membranes were incubated with affinity purified anti-mouse
antibody labeled with horseradish peroxidase (Jackson
ImmunoResearch Laboratories, West Grove, Pa.,USA) for 1 h at
room temperature under shaking. After extensive washing, mem-
branes were developed with a SuperSignal West Pico (Pierce). The
visualization of proteins was performed by chemiluminescence
detection procedure – exposure to BioMax Ms film (Sigma-
Aldrich, Corp., St. Louis, Mo., USA). The secondary antibody
controls were included in the series of Western blots. Immunoblots
were reprobed with β-actin antibody 1:10,000 (mouse monoclonal
antibody; Sigma) for normalization.
Immunohistochemistry. Tissue sections of 3 μm were mounted
on silane-coated glass slides, deparaffinized in xylene, and rehy-
drated via graded ethanols to water. Then the antigen was heat
retrieved at 95-99°C for 20 min in TRS pH 6.0 and after endoge-
nous peroxidase block slides were incubated with anti-NIS, anti-
TPO#47, anti-TIAR and anti-TIA-1 (at a concentration according
to the manufacture formula) overnight at 4°C; after washing sec-
tions were incubated with LSAB+ kit (DAKO).
All primary antibodies used were commercially available
(BD Biosciences). The reaction was developed with DAB chromo-
gene. The slides were counterstained with Mayer's hematoxylin.
The specificity of the immunostaining was checked by omission of
single steps in the protocol, replacement of the primary antibody
with preimmune serum and peptide competition tests. Slides that
showed no staining were considered negative, all other slides with
staining were considered positive. Two pathologists independently
evaluated reaction on randomly numbered slides. Expression index
was created by classifying the samples into three categories based
on the percentage of positive cells in the total number of cells
counted per field. Grade I (+) included samples with less than 10%
positive cells, grade II (++) samples had 10-50% positive cells, and
grade III (+++) samples showed more than 50% positive cells.
Ethical issues. Our study was approved by the Committee for
Ethics and Supervision on Human and Animal Research of the
Medical University of Bia³ystok.
Statistical analysis. The results were analyzed using Statistica 8.0
software. The mean values of immune parameters between groups
were evaluated using Student's t test, U Mann-Whitney's test or
Fisher's exact probability test. Correlation was assessed by Spear-
man's signed ranks test. P<0.05 was considered significant.
Results
Table 1 presents the characteristics and laboratory
findings of patients with GD (prior to methimazole
therapy and during clinical-biochemical euthyreosis
before surgery) or with NTMG (before surgery).
Patients with nodular lesions above 1 cm in size seen
on ultrasonography underwent fine-needle aspiration
biopsy, which revealed benign changes in the form of
'colloid nodular goiter'. Scintigraphy additionally per-
formed in 3 patients with nodular goiter and clinical
symptoms of hyperthyroidism showed a selective
increase in the accumulation of radioactive iodine
within the area of single nodular lesions. Postoperative
tissue material was used to identify proapoptotic regu-
latory proteins of the TIAR and TIA family by means
of immunohistochemistry and Western blot analysis. 
Identification of proapoptotic TIAR (TIA-1 related
protein) molecule in the thyroid tissues revealed 
a higher expression of this protein in patients with
Graves' disease (+++) in comparison to patients with
NTNG (+) (Figs. 1 and 2). The elevated expression of
TIAR in the thyroid tissue of patients with GD was
observed mainly in hyperfunctional thyrocytes (with
higher epithelium). The expression of TIA-1 molecule
was detected only in patients with Graves' disease (+)
in lymph nodes with germinal centers. 
The tissue material was additionally subjected to
Western blot analysis, which in GD patients showed
the presence of TIA-1 in the band p22, p17 (kDa)]
(Fig. 3a). In group of patient with NTMG presence of
TIA-1 in the band 17 (kDa) were observed (Fig. 3b).
In GD patients, Western blot analysis showed TIAR
expression in band p50, p42, p38 (kDa) (Fig. 4a). In
patients with NTNG, the degree of expression of TIAR
Fig. 1. Immunohistochemical identification of TIAR molecule in
thyrocytes from a representative patients with GD. Expression of
TIAR protein (+++). Fig. 2. Immunohistochemical identification of TIAR molecule in
thyrocytes from a representative patients with NTMG. Expression
of TIAR protein (+).
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proteins was lower and referred to band 42 (kDa) 
(Fig. 4b). Each thyroid tissue sample obtained from
our study patients underwent assessment for the pres-
ence of β-actin using the Western blot method, which
confirmed that the tissues were not degraded and indi-
cated high-quality analyses (Fig. 5). This study
showed increased expression of proapoptotic markers
in thyroid tissues from Graves' patients in comparison
to patients with nontoxic nodular goiter. 
The relationship between expression of NIS and
TPO and the expression of apoptosis regulatory mole-
cules of the TIA-1 family were taken into considera-
tion. The expression of NIS and TPO in thyroid follic-
ular cells was higher in patients with Graves' disease
(+++, +++, respectively) in comparison with their
detection in patients with NTMG (+, +, respectively)
(Fig. 6 and7). In addition, the degree of thyroid antigen
expression was positive, and correlated with the
amount of proapoptotic markers in thyroid tissues.
(TIAR, p<0.001; TIA-1, p<0.025 for NIS; TIAR,
p<0.012 for TPO). (Table 2). However, such a correla-
tion was not observed in patients with NTNG. 
Discussion
TIA-1 and TIAR are RNA binding proteins of the
RNA recognition motif (RRM)/ribonucleoprotein
(RNP) family that have been implicated as effectors of
apoptotic cell death. The molecular mechanism by
which the PID (protein-interaction domains) of an
RNAbinding protein might trigger apoptotic cell death
is not fully known. Taupin et al proposed that p15-
TIA-1(15-kDa cytotoxic granule-associated protein)
might affect the function of TIAR, a TIA-1-related
RNA-binding protein what was identified by low-
stringency hybridization. Like p40-TIA-1, TIAR pos-
sesses three N-terminal RRMs and a C-terminal PID.
The RRMs of TIA-1 and TIAR are in 90% identical at
Table 1. Clinical characteristics of the examined patients. GD –
Graves' disease NTMG – non-toxic mulitnodular goiter, * – statis-
tical significance between group with GD and group with NTMG.
Table 2. Correlation between proapoptotic molecules and thyroid
autoantigens (NIS and TPO) in thyroid tissues from patients with
Graves'disease.
Fig. 3. Identification of apoptotic TIA-1 protein by Western Blot
method in a representative patients with Graves' disease (a) and
non-toxic multinodular goiter (b).
Fig. 4. Identification of apoptotic TIAR protein by Western Blot
method in a representative patients with Graves' disease (a) and
non-toxic multinodular goiter (b).
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the amino acid level, and the PIDs are 50% identical.
Like TIA-1, TIAR triggers DNA fragmentation in per-
meabilized thymocytes, suggesting its possible
involvement in apoptosis. Results of their study show
that TIAR is a ubiquitously expressed nuclear protein
that rapidly moves to the cytoplasm in response to
exogenous triggers of apoptosis. TIAR is normally
confined to the nucleus of cells, but during Fas-medi-
ated apoptosis, it is rapidly translocated to the cyto-
plasm. Cytoplasmic redistribution precedes the onset
of DNA fragmentation and the nuclear architectural
changes that facilitate histone extraction [12].
Similar studies were conducted by Tain et al, who
proved that TIA-1 itself has been linked to apoptosis.
Fig.  5. Detection of β-actin obtained by Western Blot method in thyroid tissue from representative patients with Graves' disease and 
non-toxic multinodular goiter (NTNG); (a) expression of β-actin in patient with Graves' disease; (b) expression of β-actin in patients with
non-toxic multinodular goiter.
Fig. 6. Immunohistochemical identification of sodium/iodide symporter (NIS) and thyroid peroxidase (TPO) in thyrocytes from a repre-
sentative patient with GD; (a) expression of NIS protein (+++); (b) expression of TPO#47 protein (+++).
Fig. 7. Immunohistochemical identification of sodium/iodide symporter (NIS) and thyroid peroxidase (TPO) in thyrocytes from a repre-
sentative patient with NTMG. (a) expression of NIS protein (+). (b) expression of TPO#47 protein (+).
The serine-threonine kinase FAST is activated during
Fas-mediated apoptosis in Jurkat cells and phosphory-
lates TIA-1 prior to the onset of DNA fragmentation
[13].
In the mouse model TIAR were essential for pri-
mordial germ cell development, as it appears to be
necessary for cell survival [14]. It may be suggest that
proapoptotic stimuli modify the activities of TIA-1 and
TIAR, leading to changes in the splicing patterns of
key pre-mRNAs. 
Tsuzuki et al showed that apoptosis triggered by
20-hydroxyecdysone during pupal metamorphosis of
the silkworm Bombyx mori is accompanied by an
increase in TIAR mRNA levels [15]. Jin K. et al indi-
cated that ischemia-induced apoptosis also leads to an
increase in TIAR mRNA levels [16]. These observa-
tions also suggest that TIAR could be required for
apoptosis. TIA-1 and TIAR may normally work for
cell survival, but during apoptosis they are modified,
so as to be rendered inactive for cell survival tasks, yet
active to participate in new tasks in apoptosis progres-
sion [17].
The role of TIA and TIA-1 hasn't been explained
in thyroid autoimmunological diseases. Immunohis-
tochemistry revealed that lymphoid cells may be pos-
itive for T-cell-restricted intracellular antigen 1 (TIA-
1). Okamoto et al. described a case of patient with T-
cell lymphoma without clinical or laboratory symp-
toms of autoimmune thyroiditis. They suspected that
TIA-1 expression together with TCRb gene
rearrangement seemed categorized into TCRa/b+
cytotoxic T-cell lymphoma. Although Yamaguchi et
al. reported a case of TCRg/d+ thyroid T-cell lym-
phoma, no case of thyroid T-cell lymphoma express-
ing cytotoxic molecules such as TIA-1 has been
reported [18,19].
In our studies elevated expression of TIAR/TIA-1
in GD in comparison with its expression in non-
immune diseases indicated to enhanced apoptosis
activity in immune process. Our findings suggest that
significant expression of TIAR may indicate on
enhanced activity of egzogenous way of apoptosis in
autoimmune diseases, for example in GD. Kawakami
et al observed the association between the apoptosis of
thyrocytes and the process of autoimmune thyroid dis-
eases and suggested that Fas-mediated apoptosis of
human thyrocytes is modulated by thyroid-stimulating
antibodies, thyroid stimulation blocking antibodies
and cytokines [20]. Similarly, we conclude that elevat-
ed expression of NIS and TPO in Graves' disease is
associated with higher stimulation and activation of
apoptosis in thyroid follicular cells during autoim-
mune process. According to our knowledge the corre-
lation between NIS and TPO and apoptosis regulatory
molecules of the TIA-1 family in thyroid diseases was
not considered in any publication. Therefore more and
more observations are needed. The understanding of
the apoptotic process at the molecular level may
broaden the knowledge of the pathogenesis of autoim-
mune thyroid disorders and provide new diagnostic,
prognostic and therapeutic potentials.
We conclude that elevated expression of NIS and
TPO in Graves' disease is associated with higher stim-
ulation and activation of apoptosis in thyroid follicular
cells during autoimmune process.
References 
[ 1] Beck AR, Medley QG, O'Brien S, Anderson P, Streuli M.
Post-transcriptional regulation of tumour necrosis factor 
α production. Nucleic Acids Res. 1996;24:3829-3835.
[ 2] Förch P, Puig O, Kedersha N. et al. Modulation of msl-2 5'
splice site recognition by Sex-lethal. Mol Cell. 2000;6:1089-
1098.
[ 3] Förch P, Puig O, Martnez C, Seraphin B, Valcarcel J. U2
small nuclear ribonucleoprotein particle (snRNP) auxiliary
factor of 65 kDa, U2AF65, can promote U1 snRNP recruit-
ment to 5' splice sites. EMBO J. 2002;21:6882-6892.
[ 4] Piecyk M, Wax S, Beck AR. et al. Post-transcriptional regu-
lation of tumour necrosis factor α production. EMBO J. 2000;
19: 4154-4163.
[ 5] Yu Q, Cok SJ, Zeng C, Morrison AR. Translational Repres-
sion of Human Matrix Metalloproteinases-13 by an Alterna-
tively Spliced Form of T-cell-restricted Intracellular Antigen-
related Protein (TIAR). J Biol Chem. 2003;278:1579-1584.
[ 6] Dixon DA, Balch GC, Kedersha N. et al. Regulation of
Cyclooxygenase-2 Expression by the Translational Silencer
TIA-1. J Exp Med. 2003;198:475-481.
[ 7] Kandasamy K, Joseph K, Subramaniam K, Raymond JR,
Tholanikunnel BG. Translational Control of {beta}2-Adren-
ergic Receptor mRNA by T-cell-restricted Intracellular Anti-
gen-related Protein. J Biol Chem. 2005;280:1931-1943.
[ 8] Kawai T, Lal A, Yang X, Galba´n S, Mazan-Mamczarz K,
Gorospe M. T-cell Intracellular Antigen-1 (TIA-1)-induced
Translational Silencing Promotes the Decay of Selected
mRNAs. Mol Cell Biol. 2006;26:3295-3307.
[ 9] Lal A, Abdelmohsen K, Pullmann R et al. Post-transcription-
al derepression of GADD45α by genotoxic stress. Mol Cell.
2006;22:117-128.
[10] Izquierdo JM, Valcarcel J. Two Isoforms of the T-cell Intra-
cellular Antigen 1 (TIA-1) Splicing Factor Display Distinct
Splicing Regulation Activities. Biochem Biophys Res Com-
mun. 2006;348:703-711. 
[11] Beck AR, Medley QG, O'Brien S, Anderson P, Streuli M.
Structure, tissue distribution and genomie organization of the
murine RRM-type RNA binding proteins TIA-1 and TIAR.
Nucleic Acids Research. 1996;19:3829-3835 .
[12] Taupin J, Tian Q, Kedershat N, Robertson M, Anderson P.
The RNA-binding protein TIAR is translocated from the
nucleus to the cytoplasm during Fas-mediated apoptotic cell
Heath. Proc Natl Acad Sci USA. 1995; 92:1629-1633.
[13] Tian Q, Taupin J, Elledge S, Robertson M, Anderson P. Fas-
activated serine/threonine kinase (FAST) phosphorylates
TIA-1 during Fas-mediated apoptosis. J Exp Med. 1995;182:
865-874.
[14] Beck A, Miller I J, Anderson P, Streuli M. RNA-binding pro-
tein TIAR is essential for primordial germ cell development.
Proc Natl Acad Sci USA. 1998; 95:2331-2336. 
[15] Tsuzuki S, Iwami, M, Sakurai S. Ecdysteroid-inducible genes
in the programmed cell death during insect metamorphosis.
Insect Biochem Mol Biol. 2001;31:321-331.
183TIAR and TIA-1 expression thyroid in immune and non-immune thyroid diseases
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(2): 183 (171-177) 
10.2478/v10042-010-0022-2
184 A. Bossowski et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(2): 184 (171-177) 
10.2478/v10042-010-0022-2
[16] Jin K, Mao XO, Eshoo MW. cDNA Microarray Analysis of
Changes in Gene Expression Induced by Neuronal Hypoxia
in Vitro. Ann Neurol. 2001;50:93-103.
[17] Le Guiner C, Gesnel MC, Breathnach R. TIA-1 or TIAR Is
Required for DT40 Cell Viability. J Biol Chem.
2003;12:10465-10476.
[18] Yamaguchi M, Ohno T, Kita K. g/d T-cell lymphoma of the
thyroid gland. NEJM. 1997;336:1391-1392.
[19] Namura K, Uchiyama H, Kajita Y, Inaba T, Nakamura S, Shi-
mazaki C. Cytotoxic T-Cell Non-Hodgkin's Lymphoma of the
Thyroid Gland Akio Okamoto. Am J Hematol. 2005;8:77-78.
[20] Kawakami A, Eguchi K. Involvement of apoptotic cell death
in autoimmune diseases. Med Electron Microsc. 2002;35:1-8.
Submitted: 3 January, 2010
Accepted after reviews: 29 March, 2010
